Agilent Technologies Inc. has announced the launch of its new Dako Omnis family of instruments, featuring three models—Dako Omnis 110, 165, and 165 Duo—developed to address the evolving demands of pathology laboratories of varying sizes and workloads. This expansion marks a significant shift from a one-size-fits-all approach to a more customizable, scalable portfolio tailored to lab-specific requirements.
With this launch, Agilent empowers laboratories to select instruments based on their specific volume, workflow, and diagnostic needs:
Dako Omnis 110: Designed for low- to medium-volume labs, this model supports up to 110 IHC slides per day with consistent performance.
Dako Omnis 165: Built for medium- to high-volume labs, it delivers up to 165 IHC slides daily with optimized throughput.
Dako Omnis 165 Duo: Offering dual-mode functionality, this model enables simultaneous IHC and ISH processing, providing flexibility and high efficiency for busy labs.
All models are based on the successful original Dako Omnis platform and feature continuous, case-based processing, shared reagents, and now a direct connection to deionized water and non-hazardous waste—enhancing workflow efficiency and reducing turnaround times.
Early adopters have responded positively to the new capabilities. Jessica Barbour, Senior Biomedical Scientist at Aberdeen Royal Infirmary, noted:
"The addition of a direct connection for deionized water and the ability to empty waste while the machine runs are significant improvements. These features reduce downtime and support higher slide throughput during the day."
Majken Nielsen, Associate Vice President of Marketing and Product Management in Agilent’s Clinical Diagnostics Division, emphasized that the new models were developed in response to customer feedback:
"Pathology labs today face increasing challenges—rising test volumes, staffing limitations, and more complex diagnostics. Our expanded Dako Omnis family simplifies workflows and strengthens diagnostic performance, helping labs deliver faster, high-quality results."
The new instruments will be showcased at major upcoming events, including the European Congress of Pathology (ECP) from September 6–10, and the National Society for Histotechnology (NSH) from September 26–30. Initial product availability will include the U.S., Europe, and Australia.
This launch underscores Agilent’s continued commitment to providing innovative, flexible, and scalable diagnostic solutions that enable pathology labs to improve efficiency and support long-term growth.